Please assess the completion status of the following clinical trial:

Trial Title: A Test and Treat Strategy in New HIV Diagnosis.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years old.~2. Having confirmed HIV-1 positive test.~3. Patients not previously treated with antiretroviral treatment (post-exposure prophylaxis will be allowed if not done in the previous 6 months).~4. Clinically stable patients, in the opinion of the investigator, at the time of inclusion.~5. Women of child-bearing potential\* must have a negative pregnancy test in urine before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: hormonal contraceptive methods intrauterine device, bilateral tubal occlusion, vasectomized partner or sexual abstinence.~6. Written informed consent.~Exclusion Criteria:~1. Pregnant or breastfeeding women at the time of the study inclusion or anticipating pregnancy during the follow-up period.~2. Suspicion of an active opportunistic infection that defers initiating antiretroviral treatment \> 7 days since HIV confirmation.~3. Known hypersensitivity or intolerance of any of the components of Biktarvy®.~4. Patients on treatment with any prohibited medication (see section 5.2: Concomitant, nonpermitted and permitted medication).~5. Any condition which, in the opinion of the principal investigator, may interfere with adequate understanding, cooperation or compliance with the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biktarvy (Type: EXPERIMENTAL): This is a fixed dose combination regimen containing 50 mg of Bictegravir + 200 mg of Emtricitabine + 25 mg of Tenofovir alafenamide.

Based on this trial design, predict the completion outcome and termination type (if applicable).